ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0808

Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort
Abstract Number: 1789

Time to Renal Insufficiency Based on 25(OH)-Vitamin D Levels
Abstract Number: 0856

Time to Renal Insufficiency Based on Prior Hydroxychloroquine Blood Levels
Abstract Number: 1024

Time Trends in the Incidence of Systemic Lupus Erythematosus: A 40-Year Study
Abstract Number: 1312

Time-dependent Analysis of Incident Extra-articular Manifestations and Comorbidities in Axial Spondyloarthritis
Abstract Number: 0294

Tired T-Cells and Monocytes with Malaise: Investigating the Links Between Cellular Iron Deficiency and Mitochondrial Dysfunction in Systemic Lupus Erythematosus
Abstract Number: 0475

To Attend or Note to Attend; The Medical Student’s Dilemma
Abstract Number: 0730

To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
Abstract Number: L07

Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: 0958

Tocilizumab in Myositis: Results of a Phase IIb Double-Blind Randomized Controlled Trial
Abstract Number: 1383

Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
Abstract Number: 1039

Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis
Abstract Number: L11

Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Abstract Number: 1495

Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Abstract Number: 1527

Tofacitinib Inhibits Angiogenesis Through Its Opposite Effects on Pro- and Anti-angiogenic Factors

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].